Plus Therapeutics Shares Jump As First Patient Treated In Latest Cohort Of Brain Tumor Trial - Plus Therapeutics (NASDAQ:PSTV)

Plus Therapeutics Inc PSTV has announced that the first patient in the eighth cohort of Phase 1 dose-escalation ReSPECT-GBM trial for recurrent glioblastoma (rGBM) has been treated.
The present cohort implements a 40% increase in volume (12.3 milliliters) and total radioactivity (31.2 millicuries) from the previous cohort.
"The ReSPECT-GBM Phase 1 clinical trial is progressing on schedule and with an acceptable safety profile," said Marc H. Hedrick, President & CEO.
The Company will provide an update by the end of 2021.
22 patients across eight dosing cohorts have been treated in the ReSPECT trial to date.
Thus far, no treatment-emergent dose-limiting toxicities have been observed, despite absorbed radiation doses to the tumor of up to 740 Gray.
Price Action: PSTV shares are up 9.48% at $2.54 during the premarket session on the last check Thursday.